/**
 * @file en-US/sofa.ts
 * @description English translations for SOFA Score Calculator (COMPLETE - All sections)
 * @author Vasile Chifeac
 * @created 2025-12-14
 * @completed 2025-12-14
 *
 * @references
 * - Vincent JL et al. (1996) "The SOFA score to describe organ dysfunction" ICM. PMID: 8863252
 * - Singer M et al. (2016) "Sepsis-3 Consensus Definitions" JAMA. PMID: 26903338
 */

export default {
  // === PHASE 1: BREADCRUMB AND TITLE ===
  breadcrumbs: {
    home: 'Home',
    sofaScore: 'SOFA Score',
  },

  title: 'SOFA Score Calculator',
  subtitle:
    'Sequential Organ Failure Assessment - Multi-organ dysfunction evaluation in intensive care',

  // === PHASE 2: BANNER + FORM ===
  banner: {
    title: 'SOFA Score:',
    description:
      'Prognostic system to assess severity of organ dysfunction in critically ill patients. 6 organ systems, score 0-4 each, total 0-24 points.',
  },

  form: {
    title: 'Organ Parameters',

    // Respiration
    respiration: {
      label: 'Respiration (PaO2/FiO2)',
      options: {
        ge400: 'greater than or equal to 400',
        lt400: 'less than 400',
        lt300: 'less than 300',
        lt200: 'less than 200 with respiratory support',
        lt100: 'less than 100 with respiratory support',
      },
    },

    // Coagulation
    coagulation: {
      label: 'Coagulation (Platelets x10¬≥/microL)',
      options: {
        ge150: 'greater than or equal to 150',
        lt150: 'less than 150',
        lt100: 'less than 100',
        lt50: 'less than 50',
        lt20: 'less than 20',
      },
    },

    // Liver
    liver: {
      label: 'Liver (Bilirubin mg/dL)',
      options: {
        lt1_2: 'less than 1.2',
        range1_2_1_9: '1.2-1.9',
        range2_0_5_9: '2.0-5.9',
        range6_0_11_9: '6.0-11.9',
        ge12: 'greater than or equal to 12.0',
      },
    },

    // Cardiovascular
    cardiovascular: {
      label: 'Cardiovascular (MAP/Vasopressors)',
      options: {
        mapGe70: 'MAP greater than or equal to 70 mmHg',
        mapLt70: 'MAP less than 70 mmHg',
        dopa5Dobut: 'Dopamine less than or equal to 5 or Dobutamine any dose',
        dopa5EpiNorepi01:
          'Dopamine greater than 5 OR Epinephrine less than or equal to 0.1 OR Norepinephrine less than or equal to 0.1',
        dopa15EpiNorepi01:
          'Dopamine greater than 15 OR Epinephrine greater than 0.1 OR Norepinephrine greater than 0.1',
      },
    },

    // Central Nervous System
    cns: {
      label: 'Central Nervous System (GCS)',
      options: {
        gcs15: 'GCS 15',
        gcs13_14: 'GCS 13-14',
        gcs10_12: 'GCS 10-12',
        gcs6_9: 'GCS 6-9',
        gcsLt6: 'GCS less than 6',
      },
    },

    // Renal
    renal: {
      label: 'Renal (Creatinine mg/dL or Urine Output mL/day)',
      options: {
        lt1_2: 'less than 1.2',
        range1_2_1_9: '1.2-1.9',
        range2_0_3_4: '2.0-3.4',
        range3_5_4_9: '3.5-4.9 or less than 500 mL/day',
        ge5: 'greater than or equal to 5.0 or less than 200 mL/day',
      },
    },

    resetButton: 'Reset',
  },

  // === PHASE 3: RESULTS PANEL ===
  results: {
    title: 'SOFA Score Result',
    totalScoreLabel: 'Total Score',
    totalScoreRange: '(0-24)',

    mortalityRisk: {
      veryLow: 'Less than 10% Mortality',
      low: '15-20% Mortality',
      moderate: '40-50% Mortality',
      high: 'Greater than 80% Mortality',
      veryHigh: 'Greater than 90% Mortality',
    },

    interpretation: {
      title: 'Clinical Interpretation:',
      sofaPrefix: 'SOFA',
      mortalityRiskText: 'in-hospital mortality risk.',
      serialMonitoring:
        'Serial monitoring (every 24-48h) to assess trend. DeltaScore +2 points indicates significant deterioration.',
    },
  },

  // === PHASE 4: EXPANDABLE SECTIONS (1-3) ===
  sections: {
    // Section 1: Definition
    definition: {
      title: 'Definition and Clinical Significance',

      // Historical Origin
      historicalOriginTitle: 'Historical Origin',
      historicalOriginParagraph1:
        'The <strong>SOFA (Sequential Organ Failure Assessment) Score</strong> was developed in <strong>1996</strong> by <strong>Jean-Louis Vincent and the Sepsis-related Organ Failure Assessment Working Group</strong> at the European Society of Intensive Care Medicine consensus conference.',
      historicalOriginParagraph2:
        '<strong>Original objective:</strong> Create a simple, objective system to describe and quantify the degree of organ dysfunction over time in critically ill patients, particularly those with sepsis.',

      keyCharacteristicsTitle: '<strong>Key characteristics:</strong>',
      keyCharacteristic1: '‚úÖ Assesses <strong>6 major organ systems</strong> independently',
      keyCharacteristic2:
        '‚úÖ Each organ scored <strong>0-4 points</strong> based on severity of dysfunction',
      keyCharacteristic3: '‚úÖ Total score <strong>0-24 points</strong> (higher = worse prognosis)',
      keyCharacteristic4:
        '‚úÖ Can be calculated <strong>repeatedly</strong> to track trajectory (delta SOFA)',
      keyCharacteristic5:
        '‚úÖ Validated predictor of <strong>ICU mortality</strong> (AUROC 0.74-0.86)',

      // Clinical Applications
      clinicalApplicationsTitle: 'Clinical Applications',
      whenToUseTitle: '<strong>When to use:</strong>',
      whenToUseItem1:
        'üìä <strong>ICU admission triage:</strong> Baseline SOFA score for severity stratification',
      whenToUseItem2:
        'üìà <strong>Serial monitoring:</strong> Daily SOFA scores to detect deterioration/improvement',
      whenToUseItem3:
        'ü¶† <strong>Sepsis diagnosis (Sepsis-3):</strong> SOFA ‚â•2 points = organ dysfunction criterion',
      whenToUseItem4:
        'üî¨ <strong>Clinical trials:</strong> Standardized severity measure and outcome predictor',
      whenToUseItem5:
        'üíä <strong>Treatment decisions:</strong> Guide escalation/de-escalation of ICU care',

      whenNotToUseTitle: '<strong>When NOT to use:</strong>',
      whenNotToUseItem1:
        '‚ùå <strong>Non-ICU patients:</strong> Not validated for ward/ED populations',
      whenNotToUseItem2:
        '‚ùå <strong>Pediatrics:</strong> Use Pediatric SOFA (pSOFA) or PELOD score instead',
      whenNotToUseItem3:
        '‚ùå <strong>Single time-point prognosis:</strong> Delta SOFA more predictive than baseline alone',
      whenNotToUseItem4:
        '‚ùå <strong>Sole treatment guide:</strong> Must integrate with clinical judgment',

      limitationsTitle: '<strong>Limitations:</strong>',
      limitationItem1:
        '‚ö†Ô∏è Does NOT capture <strong>all organ systems</strong> (e.g., GI, immunologic, endocrine)',
      limitationItem2:
        '‚ö†Ô∏è Requires <strong>accurate laboratory data</strong> (may be delayed or unavailable)',
      limitationItem3:
        '‚ö†Ô∏è Confounded by <strong>chronic organ dysfunction</strong> (use baseline SOFA if known)',
      limitationItem4:
        '‚ö†Ô∏è GCS component unreliable in <strong>sedated patients</strong> (consider sedation-free assessment)',
      limitationItem5:
        '‚ö†Ô∏è <strong>Not a treatment target:</strong> Improving care ‚â† improving SOFA directly',
    },

    // Section 2: Organ Dysfunction
    organDysfunction: {
      title: 'Organ Dysfunction Physiology',

      pathophysiologicalMechanismsTitle: 'Pathophysiological Mechanisms',

      // Respiration
      respirationTitle: '1Ô∏è‚É£ Respiration (PaO‚ÇÇ/FiO‚ÇÇ ratio):',
      respirationItem1: '<strong>Normal P/F ratio:</strong> ‚â•400 mmHg (intact gas exchange)',
      respirationItem2:
        '<strong>Hypoxemia mechanisms:</strong> V/Q mismatch, shunt, diffusion impairment, hypoventilation',
      respirationItem3:
        '<strong>ARDS pathophysiology:</strong> Alveolar-capillary membrane damage ‚Üí pulmonary edema ‚Üí surfactant dysfunction',
      respirationItem4:
        '<strong>Berlin ARDS criteria:</strong> Mild P/F 200-300, Moderate 100-200, Severe &lt; 100',
      respirationItem5:
        '<strong>Critical threshold:</strong> P/F &lt;100 with respiratory support = SOFA 4 (profound ARDS, mortality >40%)',

      // Coagulation
      coagulationTitle: '2Ô∏è‚É£ Coagulation (Platelets):',
      coagulationItem1: '<strong>Normal platelets:</strong> 150-400 √ó10¬≥/ŒºL',
      coagulationItem2:
        '<strong>Thrombocytopenia causes in ICU:</strong> Consumptive coagulopathy (DIC), bone marrow suppression, dilutional, immune-mediated (HIT)',
      coagulationItem3:
        '<strong>DIC mechanisms:</strong> Systemic activation coagulation cascade ‚Üí microthrombi ‚Üí consumption clotting factors/platelets ‚Üí bleeding + thrombosis',
      coagulationItem4:
        '<strong>Bleeding risk:</strong> Platelets &lt; 50K significant spontaneous bleeding risk, &lt;20K critical (SOFA 4)',
      coagulationItem5:
        '<strong>Sepsis-associated:</strong> Thrombocytopenia in 30-50% septic patients, marker of severity',

      // Liver
      liverTitle: '3Ô∏è‚É£ Liver (Bilirubin):',
      liverItem1: '<strong>Normal bilirubin:</strong> &lt;1.2 mg/dL',
      liverItem2:
        '<strong>Hyperbilirubinemia mechanisms:</strong> Hypoxic hepatitis, cholestasis, impaired conjugation/excretion',
      liverItem3:
        '<strong>Shock liver:</strong> Acute ischemic injury (Zone 3 centrilobular necrosis) ‚Üí transaminase ‚Üë‚Üë (>1000 IU/L) + bilirubin ‚Üë',
      liverItem4:
        '<strong>Cholestasis:</strong> Sepsis-induced impaired bile flow ‚Üí conjugated hyperbilirubinemia',
      liverItem5:
        '<strong>Hepatic failure:</strong> Bilirubin ‚â•12 mg/dL (SOFA 4) with coagulopathy/encephalopathy = poor prognosis',

      // Cardiovascular
      cardiovascularTitle: '4Ô∏è‚É£ Cardiovascular (MAP/Vasopressors):',
      cardiovascularItem1: '<strong>Normal MAP:</strong> ‚â•70 mmHg (adequate tissue perfusion)',
      cardiovascularItem2:
        '<strong>Shock types:</strong> Distributive (septic), cardiogenic, hypovolemic, obstructive',
      cardiovascularItem3:
        '<strong>Septic shock pathophysiology:</strong> Vasodilation (NO, cytokines) + myocardial depression + capillary leak ‚Üí hypotension + ‚Üìtissue O‚ÇÇ delivery',
      cardiovascularItem4:
        '<strong>Vasopressor ladder:</strong> Norepinephrine 1st-line ‚Üí +Vasopressin ‚Üí +Epinephrine ‚Üí High-dose (SOFA 4 = refractory shock)',
      cardiovascularItem5:
        '<strong>Critical threshold:</strong> MAP &lt;65 mmHg or high-dose vasopressors = end-organ hypoperfusion risk',

      // CNS
      cnsTitle: '5Ô∏è‚É£ Central Nervous System (GCS):',
      cnsItem1: '<strong>Normal consciousness:</strong> GCS 15 (fully awake, oriented)',
      cnsItem2:
        '<strong>Encephalopathy mechanisms:</strong> Hypoxia, hypoperfusion, uremic toxins, hepatic encephalopathy, sepsis-associated delirium',
      cnsItem3:
        '<strong>Sedation confounding:</strong> GCS unreliable in sedated patients (consider sedation-free assessment or exclude from SOFA)',
      cnsItem4:
        '<strong>Coma (GCS &lt;6):</strong> SOFA 4 = profound CNS dysfunction, high mortality unless reversible cause',

      // Renal
      renalTitle: '6Ô∏è‚É£ Renal (Creatinine/Urine Output):',
      renalItem1:
        '<strong>Normal creatinine:</strong> 0.6-1.2 mg/dL (varies by muscle mass, age, sex)',
      renalItem2:
        '<strong>AKI mechanisms:</strong> Pre-renal (hypoperfusion), intrinsic renal (ATN, GN), post-renal (obstruction)',
      renalItem3:
        '<strong>Septic AKI:</strong> Hemodynamic (hypotension) + inflammatory (cytokine-mediated tubular injury) + microvascular dysfunction',
      renalItem4:
        '<strong>KDIGO AKI stages:</strong> Stage 1 (Cr 1.5-1.9√ó baseline), Stage 2 (2.0-2.9√ó), Stage 3 (‚â•3√ó or ‚â•4 mg/dL or RRT)',
      renalItem5:
        '<strong>Oliguria/anuria:</strong> &lt;500 mL/day (SOFA 3), &lt;200 mL/day (SOFA 4) = severe AKI, likely RRT need',
    },

    // Section 3: How to Calculate
    howToCalculate: {
      title: 'How to Calculate SOFA Score',

      calculationStepsTitle: 'Calculation Steps',

      // Step 1
      step1Title: '<strong>Step 1: Collect Worst Values (24h window)</strong>',
      step1Item1: 'üìä Use <strong>worst value</strong> for each parameter in the past 24 hours',
      step1Item2: '‚è∞ For serial SOFA: same time each day (e.g., 08:00 AM rounds)',
      step1Item3: 'üîç Ensure recent lab data: PaO‚ÇÇ, FiO‚ÇÇ, platelets, bilirubin, creatinine',
      step1Item4:
        'üíä Document MAP and any vasopressor doses (norepinephrine, dopamine, epinephrine)',
      step1Item5: 'üß† Assess GCS without sedation if possible (or note sedation influence)',
      step1Item6: 'üíß Calculate 24h urine output (total mL/24h)',

      // Step 2
      step2Title: '<strong>Step 2: Score Each Organ (0-4 points)</strong>',
      step2Item1: '<strong>Respiration:</strong> Calculate PaO‚ÇÇ/FiO‚ÇÇ ratio ‚Üí Score 0-4',
      step2Item2: '<strong>Coagulation:</strong> Platelets count √ó10¬≥/ŒºL ‚Üí Score 0-4',
      step2Item3: '<strong>Liver:</strong> Bilirubin mg/dL ‚Üí Score 0-4',
      step2Item4: '<strong>Cardiovascular:</strong> MAP and/or vasopressor doses ‚Üí Score 0-4',
      step2Item5: '<strong>CNS:</strong> Best GCS in 24h ‚Üí Score 0-4',
      step2Item6:
        '<strong>Renal:</strong> Creatinine mg/dL OR urine output ‚Üí Score 0-4 (use worse)',

      // Step 3
      step3Title: '<strong>Step 3: Sum All 6 Organ Scores</strong>',
      step3Item1:
        'üßÆ <strong>Total SOFA Score</strong> = Respiration + Coagulation + Liver + Cardiovascular + CNS + Renal',
      step3Item2: 'üìà <strong>Range:</strong> 0-24 points (minimum 0, maximum 24)',
      step3Item3:
        'üìù <strong>Documentation:</strong> Record individual organ scores + total (e.g., "SOFA 12: R3 C2 L1 CV4 CNS1 Re1")',

      // Step 4
      step4Title: '<strong>Step 4: Calculate Delta SOFA (if serial measurements)</strong>',
      step4Item1: 'Œî<strong>SOFA</strong> = SOFA(current) - SOFA(baseline or previous)',
      step4Item2:
        'üìä <strong>Interpretation:</strong> ŒîSOFA ‚â•+2 points = significant deterioration (10% ‚Üë mortality per point)',
      step4Item3:
        'üìâ <strong>Improvement:</strong> ŒîSOFA negative = organ function recovery (favorable prognosis)',
      step4Item4:
        'ü¶† <strong>Sepsis-3 definition:</strong> Infection + ŒîSOFA ‚â•2 = Sepsis (organ dysfunction)',

      // Special Considerations
      specialConsiderationsTitle: 'Special Considerations',

      respirationConsiderationsTitle: 'ü´Å Respiration (PaO‚ÇÇ/FiO‚ÇÇ):',
      respirationConsiderationsItem1:
        '<strong>Calculate P/F ratio:</strong> PaO‚ÇÇ (mmHg) / FiO‚ÇÇ (decimal, e.g., 0.40 for 40% oxygen)',
      respirationConsiderationsItem2:
        '<strong>Example:</strong> PaO‚ÇÇ 80 mmHg on FiO‚ÇÇ 0.50 ‚Üí P/F = 80/0.50 = 160 ‚Üí SOFA 3',
      respirationConsiderationsItem3:
        '<strong>Respiratory support:</strong> Score 3-4 require ventilatory support (mechanical ventilation, CPAP, high-flow)',
      respirationConsiderationsItem4:
        '<strong>If no ABG:</strong> Use SpO‚ÇÇ/FiO‚ÇÇ ratio as surrogate (less accurate)',

      cardiovascularConsiderationsTitle: 'üíä Cardiovascular (Vasopressors):',
      cardiovascularConsiderationsItem1:
        '<strong>Doses in Œºg/kg/min:</strong> Dopamine, dobutamine, epinephrine, norepinephrine',
      cardiovascularConsiderationsItem2:
        '<strong>Duration:</strong> Administered for ‚â•1 hour to count',
      cardiovascularConsiderationsItem3:
        '<strong>Combination:</strong> If multiple vasopressors ‚Üí use highest scoring agent',
      cardiovascularConsiderationsItem4:
        '<strong>MAP without vasopressors:</strong> If MAP &lt;70 mmHg without drugs ‚Üí SOFA 1',

      cnsConsiderationsTitle: 'üß† CNS (Glasgow Coma Scale):',
      cnsConsiderationsItem1:
        '<strong>Best GCS in 24h:</strong> Use highest GCS observed (avoid sedation periods if possible)',
      cnsConsiderationsItem2:
        '<strong>Sedation influence:</strong> If heavily sedated entire 24h ‚Üí consider excluding CNS from SOFA or note limitation',
      cnsConsiderationsItem3:
        '<strong>Intubated patients:</strong> Cannot assess verbal component ‚Üí use E + M only (max GCS 10)',

      renalConsiderationsTitle: 'üíß Renal (Creatinine OR Urine Output):',
      renalConsiderationsItem1:
        '<strong>Use WORSE of two:</strong> Creatinine mg/dL OR urine output mL/day',
      renalConsiderationsItem2:
        '<strong>Baseline creatinine:</strong> If chronic kidney disease known ‚Üí adjust interpretation (use ŒîSOFA renal)',
      renalConsiderationsItem3:
        '<strong>RRT patients:</strong> On dialysis ‚Üí automatically SOFA 4 for renal',
    },

    // === PHASE 5: SECTIONS 4-6 ===
    // Section 4: Formula and Scoring
    formulaScoring: {
      title: 'Formula and Scoring Tables',

      formulaTitle: 'SOFA Score Formula',
      formula: 'SOFA = Respiration + Coagulation + Liver + Cardiovascular + CNS + Renal',
      formulaSubtitle: 'Each organ scored 0-4 points ‚Üí Total range 0-24 points',

      detailedTablesTitle: 'Detailed Scoring Tables',

      // Table Headers (common)
      tableHeaderScore: 'Score',
      tableHeaderInterpretation: 'Clinical Interpretation',

      // Respiration Table
      respirationTableTitle: 'ü´Å Respiration (PaO‚ÇÇ/FiO‚ÇÇ mmHg):',
      respirationTableHeader: 'PaO‚ÇÇ/FiO‚ÇÇ Ratio',
      respiration0: '‚â•400',
      respiration0Interp: 'Normal oxygenation',
      respiration1: '&lt;400',
      respiration1Interp: 'Mild hypoxemia',
      respiration2: '&lt;300',
      respiration2Interp: 'Moderate hypoxemia (Mild ARDS)',
      respiration3: '&lt;200 + ventilation',
      respiration3Interp: 'Severe hypoxemia (Moderate ARDS)',
      respiration4: '&lt;100 + ventilation',
      respiration4Interp: 'Profound ARDS (Severe)',

      // Coagulation Table
      coagulationTableTitle: 'ü©∏ Coagulation (Platelets √ó10¬≥/ŒºL):',
      coagulationTableHeader: 'Platelet Count',
      coagulation0: '‚â•150',
      coagulation0Interp: 'Normal coagulation',
      coagulation1: '&lt;150',
      coagulation1Interp: 'Mild thrombocytopenia',
      coagulation2: '&lt;100',
      coagulation2Interp: 'Moderate thrombocytopenia',
      coagulation3: '&lt;50',
      coagulation3Interp: 'Severe (bleeding risk)',
      coagulation4: '&lt;20',
      coagulation4Interp: 'Critical (spontaneous bleeding)',

      // Liver Table
      liverTableTitle: 'üü° Liver (Bilirubin mg/dL):',
      liverTableHeader: 'Bilirubin',
      liver0: '&lt;1.2',
      liver0Interp: 'Normal liver function',
      liver1: '1.2-1.9',
      liver1Interp: 'Mild hyperbilirubinemia',
      liver2: '2.0-5.9',
      liver2Interp: 'Moderate jaundice',
      liver3: '6.0-11.9',
      liver3Interp: 'Severe hepatic dysfunction',
      liver4: '‚â•12.0',
      liver4Interp: 'Hepatic failure',

      // Cardiovascular Table
      cardiovascularTableTitle: '‚ù§Ô∏è Cardiovascular (MAP/Vasopressors):',
      cardiovascularTableHeader: 'MAP or Vasopressor Doses',
      cardiovascular0: 'MAP ‚â•70 mmHg',
      cardiovascular1: 'MAP &lt;70 mmHg',
      cardiovascular2: 'Dopamine ‚â§5 OR Dobutamine (any)',
      cardiovascular3: 'Dopamine >5 OR Epi ‚â§0.1 OR Norepi ‚â§0.1 (Œºg/kg/min)',
      cardiovascular4: 'Dopamine >15 OR Epi >0.1 OR Norepi >0.1 (Œºg/kg/min)',

      // CNS Table
      cnsTableTitle: 'üß† CNS (Glasgow Coma Scale):',
      cnsTableHeader: 'GCS',
      cns0: '15',
      cns0Interp: 'Fully awake and oriented',
      cns1: '13-14',
      cns1Interp: 'Mild altered mental status',
      cns2: '10-12',
      cns2Interp: 'Moderate confusion/drowsiness',
      cns3: '6-9',
      cns3Interp: 'Severe coma (localizes pain)',
      cns4: '&lt;6',
      cns4Interp: 'Deep coma (no response)',

      // Renal Table
      renalTableTitle: 'üíß Renal (Creatinine mg/dL OR Urine Output):',
      renalTableHeader: 'Creatinine OR Urine Output',
      renal0: '&lt;1.2 mg/dL',
      renal1: '1.2-1.9 mg/dL',
      renal2: '2.0-3.4 mg/dL',
      renal3: '3.5-4.9 mg/dL OR &lt;500 mL/day',
      renal4: '‚â•5.0 mg/dL OR &lt;200 mL/day OR RRT',

      // Delta SOFA Section
      deltaSofaTitle: 'Delta SOFA (ŒîSOFA) Calculation',
      deltaSofaFormula: 'ŒîSOFA = SOFA(current) - SOFA(baseline)',
      deltaSofaItem1:
        '<strong>Baseline:</strong> First SOFA score on ICU admission OR pre-illness baseline if known',
      deltaSofaItem2:
        '<strong>ŒîSOFA ‚â•+2:</strong> Sepsis criterion (Sepsis-3 definition), 10% increased mortality per point',
      deltaSofaItem3:
        '<strong>ŒîSOFA negative:</strong> Improving organ function (favorable trajectory)',
      deltaSofaItem4:
        '<strong>ŒîSOFA +3-4:</strong> Significant clinical deterioration, reassess treatment',
    },

    // Section 5: Clinical Interpretation
    clinicalInterpretation: {
      title: 'Clinical Interpretation and Mortality Prediction',

      mortalityRiskTitle: 'Mortality Risk Stratification',

      // Risk Level 1 (0-6)
      riskLevel1Chip: 'SOFA 0-6: Low Risk',
      riskLevel1Mortality: '<strong>Mortality risk:</strong> &lt;10-15% in-hospital mortality',
      riskLevel1Status:
        '<strong>Clinical status:</strong> Mild organ dysfunction or single organ involvement',
      riskLevel1Course:
        '<strong>ICU course:</strong> Typically shorter ICU stay, good recovery potential',
      riskLevel1Management:
        '<strong>Management:</strong> Standard ICU care, monitor for deterioration',

      // Risk Level 2 (7-9)
      riskLevel2Chip: 'SOFA 7-9: Moderate Risk',
      riskLevel2Mortality: '<strong>Mortality risk:</strong> 15-20% in-hospital mortality',
      riskLevel2Status: '<strong>Clinical status:</strong> Moderate multi-organ dysfunction',
      riskLevel2Course:
        '<strong>ICU course:</strong> Prolonged ICU stay likely, requires close monitoring',
      riskLevel2Management:
        '<strong>Management:</strong> Aggressive organ support, daily SOFA trending',

      // Risk Level 3 (10-12)
      riskLevel3Chip: 'SOFA 10-12: High Risk',
      riskLevel3Mortality: '<strong>Mortality risk:</strong> 40-50% in-hospital mortality',
      riskLevel3Status: '<strong>Clinical status:</strong> Severe multi-organ failure',
      riskLevel3Course: '<strong>ICU course:</strong> Very prolonged ICU stay, complex management',
      riskLevel3Management:
        '<strong>Management:</strong> Maximum organ support, consider advanced therapies (ECMO, RRT, etc.)',

      // Risk Level 4 (13-14)
      riskLevel4Chip: 'SOFA 13-14: Very High Risk',
      riskLevel4Mortality: '<strong>Mortality risk:</strong> 50-95% in-hospital mortality',
      riskLevel4Status: '<strong>Clinical status:</strong> Profound multiple organ failure',
      riskLevel4Course: '<strong>ICU course:</strong> Salvage therapy, extremely poor prognosis',
      riskLevel4Management:
        '<strong>Management:</strong> Maximum ICU resources, family discussions about goals of care',

      // Risk Level 5 (\u226515)
      riskLevel5Chip: 'SOFA \u226515: Catastrophic',
      riskLevel5Mortality: '<strong>Mortality risk:</strong> >90% in-hospital mortality',
      riskLevel5Status:
        '<strong>Clinical status:</strong> Multi-organ failure with extremely poor prognosis',
      riskLevel5Course: '<strong>ICU course:</strong> Survival extremely rare',
      riskLevel5Management:
        '<strong>Management:</strong> Palliative care discussions appropriate, withdrawal of care may be considered',

      // Delta SOFA Interpretation
      deltaSofaInterpretationTitle: 'Delta SOFA (\u0394SOFA) Interpretation',
      deltaSofaItem1:
        '<strong>\u0394SOFA +1 point:</strong> ~10% increased mortality risk per point increase',
      deltaSofaItem2:
        '<strong>\u0394SOFA \u2265+2 points (within 48h):</strong> Sepsis-3 criterion for organ dysfunction. Significant clinical deterioration. Triggers sepsis bundle protocols (antibiotics, fluid resuscitation, source control).',
      deltaSofaItem3:
        '<strong>\u0394SOFA +3-4 points:</strong> Severe deterioration, reassess diagnosis and treatment. Consider missed infection source, resistant organisms, complications.',
      deltaSofaItem4:
        '<strong>\u0394SOFA negative (decreasing):</strong> Improving organ function, favorable trajectory. Treatment effective, consider de-escalation when appropriate.',
      deltaSofaItem5:
        '<strong>\u0394SOFA plateau (unchanged):</strong> Static course, neither improving nor worsening. May indicate chronic organ dysfunction or treatment equilibrium.',

      // Sepsis-3 Integration
      sepsis3Title: 'Sepsis-3 Definition Integration',
      sepsis3Definition:
        '<strong>Sepsis (Sepsis-3):</strong> Life-threatening organ dysfunction caused by dysregulated host response to infection',
      sepsis3Criteria:
        '<strong>Criteria:</strong> Suspected or documented infection + <strong>\u0394SOFA \u22652 points</strong>',
      sepsis3Baseline:
        '<strong>Baseline SOFA:</strong> Assume 0 if no pre-existing organ dysfunction known',
      sepsis3Shock:
        '<strong>Septic Shock:</strong> Sepsis + vasopressor requirement (MAP \u226565 mmHg) + lactate >2 mmol/L despite adequate fluid resuscitation',
      sepsis3Mortality:
        '<strong>Mortality:</strong> Sepsis ~10%, Septic Shock ~40% in-hospital mortality',

      // Clinical Pearl
      clinicalPearlTitle: 'Clinical Pearl:',
      clinicalPearlText:
        'Serial SOFA trending (daily) is MORE predictive than single baseline SOFA. Worsening \u0394SOFA indicates treatment failure or complications. Improving \u0394SOFA validates treatment efficacy.',
    },

    // Section 6: Clinical Applications
    clinicalApplications: {
      title: 'Clinical Applications of the SOFA Score',

      primaryUsesTitle: 'Primary Clinical Uses',

      // 1. Sepsis Diagnosis
      use1Title: '1Ô∏è‚É£ Sepsis Diagnosis and Severity Stratification (Sepsis-3)',
      use1Item1:
        '<strong>Screening:</strong> qSOFA (quick SOFA) ‚â•2 ‚Üí triggers full SOFA calculation',
      use1Item2: '<strong>Diagnosis:</strong> Infection + ŒîSOFA ‚â•2 = Sepsis (organ dysfunction)',
      use1Item3:
        '<strong>Severity:</strong> Baseline SOFA 0-6 (less severe), 7-12 (moderate), ‚â•13 (severe)',
      use1Item4: '<strong>Septic shock:</strong> Sepsis + vasopressors + lactate >2 mmol/L',
      use1Item5:
        '<strong>Triggers:</strong> SOFA ‚â•2 ‚Üí initiate sepsis bundles (1-hour bundle: blood cultures, antibiotics, fluid resuscitation)',

      // 2. ICU Triage
      use2Title: '2Ô∏è‚É£ ICU Admission Triage and Bed Allocation',
      use2Item1:
        '<strong>Baseline SOFA >10:</strong> High-risk patient, requires intensive monitoring and resources',
      use2Item2:
        '<strong>Resource allocation:</strong> Prioritize ICU beds for SOFA >8 during surge capacity',
      use2Item3:
        '<strong>Step-down criteria:</strong> SOFA decreasing to &lt;6 with stable trend ‚Üí consider ICU discharge to step-down unit',
      use2Item4:
        '<strong>Prognosis discussion:</strong> SOFA ‚â•15 ‚Üí poor prognosis, discuss goals of care with family',

      // 3. Serial Monitoring
      use3Title: '3Ô∏è‚É£ Serial Monitoring and Deterioration Detection',
      use3Item1:
        '<strong>Daily SOFA:</strong> Calculate at same time each day (e.g., morning rounds 08:00)',
      use3Item2:
        '<strong>Trend analysis:</strong> Graph SOFA over time to visualize trajectory (improving vs worsening)',
      use3Item3:
        '<strong>Alert thresholds:</strong> ŒîSOFA ‚â•+2 in 24-48h ‚Üí clinical alert, reassess treatment plan',
      use3Item4:
        '<strong>Organ-specific deterioration:</strong> Track individual organ scores to identify failing system (e.g., renal SOFA 0‚Üí3 = new AKI)',

      // 4. Clinical Trials
      use4Title: '4Ô∏è‚É£ Clinical Trial Endpoints and Research',
      use4Item1:
        '<strong>Inclusion criteria:</strong> Many sepsis trials require baseline SOFA ‚â•2 or specific organ SOFA thresholds',
      use4Item2:
        '<strong>Primary outcome:</strong> ŒîSOFA at day 7 or ICU discharge used as efficacy endpoint',
      use4Item3:
        '<strong>Stratification:</strong> Randomize by baseline SOFA categories (e.g., &lt;8 vs ‚â•8) to balance severity',
      use4Item4:
        '<strong>Standardized measure:</strong> Allows comparison across international studies and institutions',

      // 5. Family Communication
      use5Title: '5Ô∏è‚É£ Prognostic Communication with Families',
      use5Item1:
        '<strong>Baseline SOFA 8-12:</strong> "Your family member has moderate organ dysfunction, 15-50% mortality risk, prolonged ICU stay expected"',
      use5Item2:
        '<strong>SOFA ‚â•15:</strong> "Catastrophic multi-organ failure, >90% mortality, palliative care discussions appropriate"',
      use5Item3:
        '<strong>Improving ŒîSOFA:</strong> "Organ function recovering, treatment effective, favorable prognosis"',
      use5Item4:
        '<strong>Worsening ŒîSOFA:</strong> "Condition deteriorating despite treatment, need to reassess goals of care"',

      // 6. Quality Metrics
      use6Title: '6Ô∏è‚É£ Quality Metrics and ICU Performance',
      use6Item1:
        '<strong>Severity-adjusted mortality:</strong> Compare observed vs predicted mortality (Standardized Mortality Ratio)',
      use6Item2:
        '<strong>ICU benchmarking:</strong> SOFA used in APACHE IV, SAPS 3 models for severity adjustment',
      use6Item3:
        '<strong>Length of stay prediction:</strong> Baseline SOFA correlates with ICU LOS and mechanical ventilation days',
      use6Item4:
        '<strong>Risk stratification:</strong> Report outcomes stratified by SOFA categories for quality improvement',

      // qSOFA Section
      qsofaTitle: 'qSOFA (quick SOFA) Screening Tool',
      qsofaPurpose:
        '<strong>Purpose:</strong> Rapid bedside screening for sepsis risk (ED, ward, pre-hospital)',
      qsofaItem1:
        '<strong>Criteria (1 point each):</strong> (1) Respiratory rate ‚â•22/min, (2) Altered mental status (GCS &lt;15), (3) Systolic BP ‚â§100 mmHg',
      qsofaItem2:
        '<strong>qSOFA ‚â•2:</strong> Positive screen ‚Üí calculate full SOFA score, initiate sepsis workup',
      qsofaItem3:
        '<strong>Advantages:</strong> No lab tests required, fast bedside assessment (1 minute)',
      qsofaItem4:
        '<strong>Limitations:</strong> Lower sensitivity than full SOFA (more false negatives), not for diagnosis (screening only)',
    },

    // === PHASE 6: SECTIONS 7-9 + FOOTER ===
    // Section 7: Reference Values
    referenceValues: {
      title: 'Reference Values and Critical Alerts',

      organThresholdsTitle: 'Organ-Specific Critical Thresholds',

      // Respiration
      respirationTitle: 'ü´Å Respiration:',
      respirationItem1:
        '<strong>Normal P/F ratio:</strong> ‚â•400 mmHg (room air or minimal supplemental O‚ÇÇ)',
      respirationItem2: '<strong>Mild ARDS:</strong> P/F 200-300 (SOFA 2, moderate hypoxemia)',
      respirationItem3:
        '<strong>Moderate ARDS:</strong> P/F 100-200 (SOFA 3, severe hypoxemia, requires ventilation)',
      respirationItem4:
        '<strong>Severe ARDS:</strong> P/F &lt;100 (SOFA 4, refractory hypoxemia, consider ECMO, proning, recruitment maneuvers)',
      respirationItem5:
        '<strong>‚ö†Ô∏è ALERT:</strong> P/F &lt;100 despite optimal ventilation ‚Üí rescue therapies (ECMO, prone positioning, inhaled NO)',

      // Coagulation
      coagulationTitle: 'ü©∏ Coagulation:',
      coagulationItem1: '<strong>Normal platelets:</strong> 150-400 √ó10¬≥/ŒºL',
      coagulationItem2:
        '<strong>Moderate thrombocytopenia:</strong> 50-100K (SOFA 2-3, monitor bleeding risk)',
      coagulationItem3:
        '<strong>Severe thrombocytopenia:</strong> &lt;50K (SOFA 3, prophylactic platelet transfusion if procedures/bleeding)',
      coagulationItem4:
        '<strong>Critical thrombocytopenia:</strong> &lt;20K (SOFA 4, spontaneous bleeding risk, urgent platelet transfusion)',
      coagulationItem5:
        '<strong>‚ö†Ô∏è ALERT:</strong> Platelets &lt;20K + active bleeding ‚Üí emergent transfusion, consider DIC workup (PT/PTT, fibrinogen, D-dimer)',

      // Liver
      liverTitle: 'üü° Liver:',
      liverItem1: '<strong>Normal bilirubin:</strong> &lt;1.2 mg/dL',
      liverItem2:
        '<strong>Moderate hyperbilirubinemia:</strong> 2-6 mg/dL (SOFA 2, jaundice visible)',
      liverItem3:
        '<strong>Severe hepatic dysfunction:</strong> 6-12 mg/dL (SOFA 3, consider hepatic encephalopathy risk)',
      liverItem4:
        '<strong>Hepatic failure:</strong> ‚â•12 mg/dL (SOFA 4, check coagulation, ammonia, consider liver transplant evaluation)',
      liverItem5:
        '<strong>‚ö†Ô∏è ALERT:</strong> Bilirubin ‚â•12 + INR >2.0 + encephalopathy ‚Üí acute liver failure, hepatology consult urgent',

      // Cardiovascular
      cardiovascularTitle: '‚ù§Ô∏è Cardiovascular:',
      cardiovascularItem1: '<strong>Normal MAP:</strong> ‚â•70 mmHg without vasopressors',
      cardiovascularItem2:
        '<strong>Hypotension:</strong> MAP &lt;70 mmHg (SOFA 1, fluid resuscitation)',
      cardiovascularItem3:
        '<strong>Low-dose vasopressors:</strong> Dopamine ‚â§5 or dobutamine (SOFA 2)',
      cardiovascularItem4:
        '<strong>Moderate vasopressors:</strong> Dopamine >5 or low-dose epi/norepi (SOFA 3, septic shock)',
      cardiovascularItem5:
        '<strong>High-dose vasopressors:</strong> Dopamine >15 or high-dose epi/norepi (SOFA 4, refractory shock)',
      cardiovascularItem6:
        '<strong>‚ö†Ô∏è ALERT:</strong> SOFA CV 4 (refractory shock) ‚Üí exclude tamponade, tension pneumothorax, PE, consider ECMO, stress-dose steroids',

      // CNS
      cnsTitle: 'üß† CNS:',
      cnsItem1: '<strong>Normal consciousness:</strong> GCS 15 (fully awake)',
      cnsItem2: '<strong>Mild AMS:</strong> GCS 13-14 (SOFA 1, confusion/disorientation)',
      cnsItem3: '<strong>Moderate AMS:</strong> GCS 10-12 (SOFA 2, drowsy but arousable)',
      cnsItem4:
        '<strong>Severe coma:</strong> GCS 6-9 (SOFA 3, localizes pain, consider intubation for airway protection)',
      cnsItem5: '<strong>Deep coma:</strong> GCS &lt;6 (SOFA 4, no response, poor prognosis)',
      cnsItem6:
        '<strong>‚ö†Ô∏è ALERT:</strong> GCS &lt;6 + fixed dilated pupils ‚Üí brain death evaluation, CT head urgent',

      // Renal
      renalTitle: 'üíß Renal:',
      renalItem1:
        '<strong>Normal creatinine:</strong> 0.6-1.2 mg/dL (varies by age/sex/muscle mass)',
      renalItem2:
        '<strong>AKI Stage 1:</strong> Cr 1.2-1.9 (SOFA 1, monitor, optimize hemodynamics)',
      renalItem3:
        '<strong>AKI Stage 2:</strong> Cr 2.0-3.4 (SOFA 2, nephrology aware, avoid nephrotoxins)',
      renalItem4:
        '<strong>AKI Stage 3:</strong> Cr 3.5-4.9 or oliguria &lt;500 mL/day (SOFA 3, consider RRT soon)',
      renalItem5:
        '<strong>Renal failure:</strong> Cr ‚â•5.0 or anuria &lt;200 mL/day (SOFA 4, RRT indicated)',
      renalItem6:
        '<strong>‚ö†Ô∏è ALERT:</strong> SOFA Renal 4 + hyperkalemia (K+ >6.5) or pulmonary edema ‚Üí emergent dialysis',

      // Critical Alert Thresholds
      criticalAlertsTitle: 'Critical SOFA Alert Thresholds',
      alert1Title: 'SOFA ‚â•15',
      alert1Description:
        'Catastrophic multi-organ failure. >90% mortality. Palliative care discussions appropriate.',
      alert2Title: 'ŒîSOFA ‚â•+2 in 24-48h',
      alert2Description:
        'Sepsis criterion. Significant deterioration. Reassess diagnosis, treatment, infection source control.',
      alert3Title: 'Any single organ SOFA 4',
      alert3Description:
        'Severe single organ failure. High risk. Requires aggressive organ-specific support (e.g., ECMO for respiratory SOFA 4, RRT for renal SOFA 4).',
      alert4Title: 'SOFA 10-12',
      alert4Description:
        'High risk. 40-50% mortality. Very prolonged ICU course expected. Maximum organ support indicated.',

      // Baseline and Chronic Dysfunction
      baselineTitle: 'Baseline and Chronic Organ Dysfunction',
      baselineItem1:
        '<strong>Known baseline SOFA:</strong> If chronic organ dysfunction pre-illness (e.g., ESRD, cirrhosis, COPD) ‚Üí use pre-illness baseline SOFA for ŒîSOFA calculation',
      baselineItem2:
        '<strong>Dialysis patients:</strong> Renal SOFA automatically 4 (on RRT) ‚Üí focus on other organ scores',
      baselineItem3:
        '<strong>Elderly/frail:</strong> May have higher baseline SOFA (e.g., mild renal impairment Cr 1.5) ‚Üí interpret absolute SOFA with caution, ŒîSOFA more valuable',
      baselineItem4:
        '<strong>Pediatrics:</strong> SOFA not validated &lt;18 years ‚Üí use Pediatric SOFA (pSOFA) or PELOD-2 score instead',
    },

    // Section 8: Documentation
    documentation: {
      title: 'Medical Documentation and Guidelines',

      guidelinesTitle: 'International Guidelines and Consensus Definitions',

      // Sepsis-3
      sepsis3GuideTitle: 'üìã Sepsis-3 Consensus Definitions (2016)',
      sepsis3Item1:
        '<strong>Task Force:</strong> Society of Critical Care Medicine (SCCM) + European Society of Intensive Care Medicine (ESICM)',
      sepsis3Item2:
        '<strong>Sepsis definition:</strong> Life-threatening organ dysfunction caused by dysregulated host response to infection, operationalized as <strong>SOFA score ‚â•2 points</strong> from baseline',
      sepsis3Item3:
        '<strong>Septic shock definition:</strong> Sepsis + vasopressor requirement to maintain MAP ‚â•65 mmHg + serum lactate >2 mmol/L despite adequate fluid resuscitation',
      sepsis3Item4:
        '<strong>qSOFA screening:</strong> Respiratory rate ‚â•22/min, altered mental status (GCS &lt;15), systolic BP ‚â§100 mmHg (‚â•2 of 3 ‚Üí positive screen)',
      sepsis3Item5:
        '<strong>Impact:</strong> Replaced SIRS criteria (Sepsis-1/2 definitions). SOFA-based definition improves prognostic accuracy and clinical relevance.',

      // Surviving Sepsis Campaign
      sscGuideTitle: 'üìã Surviving Sepsis Campaign Guidelines (2021)',
      sscItem1:
        '<strong>1-Hour Bundle:</strong> Measure lactate, obtain blood cultures before antibiotics, administer broad-spectrum antibiotics, begin rapid fluid resuscitation (30 mL/kg crystalloid) if sepsis/septic shock suspected',
      sscItem2:
        '<strong>SOFA role:</strong> Used to confirm organ dysfunction (SOFA ‚â•2 from baseline) and guide treatment escalation',
      sscItem3:
        '<strong>Serial monitoring:</strong> Daily SOFA scores recommended to assess treatment response and guide de-escalation',
      sscItem4:
        '<strong>Vasopressor guidelines:</strong> Norepinephrine first-line, target MAP ‚â•65 mmHg, add vasopressin or epinephrine if refractory (aligns with SOFA cardiovascular scoring)',

      // Berlin ARDS
      ardsGuideTitle: 'üìã Berlin ARDS Definition (2012)',
      ardsItem1:
        '<strong>Integration with SOFA:</strong> SOFA respiration component based on P/F ratio aligns with Berlin ARDS severity categories',
      ardsItem2: '<strong>Mild ARDS:</strong> P/F 200-300 (SOFA respiratory 2)',
      ardsItem3: '<strong>Moderate ARDS:</strong> P/F 100-200 (SOFA respiratory 3)',
      ardsItem4: '<strong>Severe ARDS:</strong> P/F &lt;100 (SOFA respiratory 4)',
      ardsItem5:
        '<strong>Ventilation requirement:</strong> SOFA 3-4 require respiratory support (mechanical ventilation, CPAP, or high-flow nasal cannula ‚â•10 L/min)',

      // KDIGO AKI
      kdigoAkiGuideTitle: 'üìã KDIGO AKI Guidelines (2012)',
      kdigoItem1:
        '<strong>AKI staging:</strong> Stage 1 (Cr 1.5-1.9√ó baseline), Stage 2 (2.0-2.9√ó), Stage 3 (‚â•3√ó or ‚â•4 mg/dL or RRT) partially aligns with SOFA renal scoring',
      kdigoItem2:
        '<strong>Urine output criteria:</strong> SOFA uses &lt;500 mL/day (SOFA 3) and &lt;200 mL/day (SOFA 4), similar to KDIGO AKI UO criteria',
      kdigoItem3:
        '<strong>RRT indication:</strong> SOFA renal 4 often indicates RRT candidacy (severe AKI, oliguria/anuria)',

      // Best Practices
      bestPracticesTitle: 'Clinical Documentation Best Practices',

      templateTitle: 'üìù SOFA Score Documentation Template:',
      templateContent:
        'ICU Day 3 - SOFA Score:\n\nTotal SOFA: 12 (‚Üë from Day 2 SOFA 10, ŒîSOFA +2)\n\nIndividual Organ Scores:\n- Respiration: 3 (P/F ratio 180 mmHg on FiO‚ÇÇ 0.60, intubated)\n- Coagulation: 2 (Platelets 95 √ó10¬≥/ŒºL, ‚Üì from 120K)\n- Liver: 1 (Bilirubin 1.8 mg/dL)\n- Cardiovascular: 4 (Norepinephrine 0.25 Œºg/kg/min, MAP 68 mmHg)\n- CNS: 1 (GCS 14, sedation off for assessment)\n- Renal: 1 (Creatinine 1.7 mg/dL, UO 1200 mL/24h)\n\nClinical Interpretation:\nHigh-risk patient with severe multi-organ dysfunction.\nŒîSOFA +2 indicates deterioration despite antibiotics/fluids.\n\nAction Plan:\n1. Broaden antibiotics (add antifungal coverage)\n2. Increase vasopressor support (MAP target 65-70 mmHg)\n3. CT abdomen for source control evaluation\n4. Family meeting to discuss prognosis (40-50% mortality risk)\n5. Continue daily SOFA trending',

      trendingTitle: 'üìä Serial SOFA Trending Chart (recommend in EMR):',
      trendingItem1:
        '<strong>Daily total SOFA:</strong> Graph over ICU stay to visualize trajectory',
      trendingItem2:
        '<strong>Organ-specific trends:</strong> Track individual organ scores to identify specific failures (e.g., renal SOFA 0‚Üí3 = new AKI)',
      trendingItem3:
        '<strong>Color-coding:</strong> Green (SOFA 0-6), Orange (7-12), Red (‚â•13) for quick severity assessment',
      trendingItem4:
        '<strong>Annotations:</strong> Mark major interventions (e.g., "Day 2: Antibiotics changed", "Day 4: Source control surgery")',

      // Research Applications
      researchTitle: 'Research and Quality Improvement Applications',
      researchItem1:
        '<strong>Clinical trial stratification:</strong> Randomize by baseline SOFA (&lt;8 vs ‚â•8) to balance severity between arms',
      researchItem2:
        '<strong>Primary endpoints:</strong> ŒîSOFA at day 7, SOFA-free days (days alive and with SOFA &lt;6), organ failure-free days',
      researchItem3:
        '<strong>Secondary endpoints:</strong> Individual organ SOFA scores (e.g., respiratory SOFA improvement in ARDS trial)',
      researchItem4:
        '<strong>ICU benchmarking:</strong> Severity-adjusted outcomes using SOFA in APACHE IV, SAPS 3 models',
      researchItem5:
        '<strong>Quality metrics:</strong> Sepsis mortality stratified by baseline SOFA for hospital quality reporting',
    },

    // Section 9: Scientific References
    scientificReferences: {
      title: 'Scientific References (PMID Citations)',
      publicationsTitle: 'Key Publications and PMID Citations',

      // Publication 1: Vincent 1996 - Original SOFA
      publication1Author: 'üìÑ Vincent JL, Moreno R, Takala J, et al. (1996)',
      publication1Title:
        '"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure"',
      publication1Journal: '<em>Intensive Care Medicine</em>, 22(7): 707-710',
      publication1Pmid: '<strong>PMID: 8863252</strong>',
      publication1Description:
        '<strong>Original SOFA score publication.</strong> Developed by European Society of Intensive Care Medicine working group. Validated in 1449 ICU patients. Proposed 6-organ scoring system (0-4 each, total 0-24). Demonstrated correlation with ICU mortality (SOFA ‚â•15 ‚Üí >90% mortality). Emphasized utility for <strong>serial assessment</strong> (delta SOFA) rather than single time-point.',

      // Publication 2: Singer 2016 - Sepsis-3
      publication2Author: 'üìÑ Singer M, Deutschman CS, Seymour CW, et al. (2016)',
      publication2Title:
        '"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)"',
      publication2Journal: '<em>JAMA</em>, 315(8): 801-810',
      publication2Pmid: '<strong>PMID: 26903338</strong>',
      publication2Description:
        '<strong>Sepsis-3 consensus definitions.</strong> SCCM + ESICM task force. Redefined sepsis as "life-threatening organ dysfunction (SOFA ‚â•2 from baseline) caused by dysregulated host response to infection". Replaced SIRS criteria. Introduced qSOFA screening tool. Validated in 148,907 patients across 12 databases. SOFA ‚â•2 had <strong>superior predictive validity</strong> vs SIRS (AUROC 0.74 vs 0.64 for in-hospital mortality).',

      // Publication 3: Ferreira 2001 - Serial SOFA
      publication3Author: 'üìÑ Ferreira FL, Bota DP, Bross A, et al. (2001)',
      publication3Title:
        '"Serial evaluation of the SOFA score to predict outcome in critically ill patients"',
      publication3Journal: '<em>JAMA</em>, 286(14): 1754-1758',
      publication3Pmid: '<strong>PMID: 11594901</strong>',
      publication3Description:
        '<strong>Validation of serial SOFA monitoring.</strong> Studied 352 ICU patients with serial SOFA measurements. Demonstrated that <strong>ŒîSOFA during first 48h</strong> is strong predictor of mortality (ŒîSOFA +1 point = ~10% ‚Üë mortality). Patients with SOFA ‚â•11 or increasing SOFA had <strong>mortality rate >80%</strong>. Concluded serial assessment superior to single admission SOFA for prognostication.',

      // Publication 4: Seymour 2016 - Sepsis-3 Validation
      publication4Author: 'üìÑ Seymour CW, Liu VX, Iwashyna TJ, et al. (2016)',
      publication4Title:
        '"Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)"',
      publication4Journal: '<em>JAMA</em>, 315(8): 762-774',
      publication4Pmid: '<strong>PMID: 26903335</strong>',
      publication4Description:
        '<strong>Sepsis-3 validation study.</strong> Analyzed 148,907 patients with suspected infection across 12 international datasets. Compared SOFA, SIRS, LODS, qSOFA for predicting in-hospital mortality. <strong>SOFA ‚â•2 points:</strong> AUROC 0.74 (95% CI 0.73-0.76), sensitivity 63%, specificity 79% for mortality. <strong>qSOFA ‚â•2:</strong> AUROC 0.66 outside ICU, faster bedside screening but lower sensitivity than SOFA.',

      // Publication 5: Raith 2017 - ICU Validation
      publication5Author: 'üìÑ Raith EP, Udy AA, Bailey M, et al. (2017)',
      publication5Title:
        '"Prognostic Accuracy of the SOFA Score, SIRS Criteria, and qSOFA Score for In-Hospital Mortality Among Adults With Suspected Infection Admitted to the Intensive Care Unit"',
      publication5Journal: '<em>JAMA</em>, 317(3): 290-300',
      publication5Pmid: '<strong>PMID: 28114553</strong>',
      publication5Description:
        '<strong>Large ICU validation study.</strong> 184,875 ICU patients with suspected infection from Australia/New Zealand ICU databases. <strong>SOFA score:</strong> AUROC 0.753 for hospital mortality, superior to SIRS (AUROC 0.589) and qSOFA (AUROC 0.690). Baseline SOFA ‚â•2 identified 93% of ICU patients who died. Confirmed <strong>SOFA as best discriminator</strong> for organ dysfunction and mortality in ICU sepsis.',

      // Publication 6: Lambden 2019 - Comprehensive Review
      publication6Author: 'üìÑ Lambden S, Laterre PF, Levy MM, Francois B. (2019)',
      publication6Title:
        '"The SOFA score‚Äîdevelopment, utility and challenges of accurate assessment in clinical trials"',
      publication6Journal: '<em>Critical Care</em>, 23(1): 374',
      publication6Pmid: '<strong>PMID: 31775846</strong>',
      publication6Description:
        '<strong>Comprehensive SOFA review.</strong> Historical development from 1996 inception to Sepsis-3 integration. Discusses <strong>challenges:</strong> sedation confounding CNS score, chronic organ dysfunction baseline adjustments, inter-rater variability. Provides recommendations for standardized SOFA calculation in clinical trials: worst values per 24h window, sedation-free GCS when possible, document baseline SOFA for chronic disease. Reviews validation data showing <strong>consistent AUROC 0.74-0.86</strong> across diverse ICU populations.',

      // Additional References Section
      additionalTitle: 'Additional Key References',
      additionalItem1:
        '<strong>Jones AE, Trzeciak S, Kline JA.</strong> (2009) "The Sequential Organ Failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation". <em>Critical Care Medicine</em>, 37(5): 1649-1654. <strong>PMID: 19325482</strong>. ED validation showing SOFA predicted mortality better than APACHE II in sepsis patients.',
      additionalItem2:
        '<strong>Moreno R, Vincent JL, Matos R, et al.</strong> (1999) "The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study". <em>Intensive Care Medicine</em>, 25(7): 686-696. <strong>PMID: 10470572</strong>. Maximum SOFA during ICU stay predicts mortality (AUROC 0.86).',
      additionalItem3:
        '<strong>Rhodes A, Evans LE, Alhazzani W, et al.</strong> (2017) "Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016". <em>Intensive Care Medicine</em>, 43(3): 304-377. <strong>PMID: 28101605</strong>. Surviving Sepsis Campaign guidelines recommending SOFA for sepsis diagnosis and monitoring.',

      // Educational Note
      educationalNote:
        '<strong>Educational Note:</strong> These references represent peer-reviewed, high-impact publications validating SOFA score. PMID citations allow direct PubMed lookup. The SOFA score has been validated across >300,000 ICU patients in multiple international cohorts, consistently demonstrating AUROC 0.74-0.86 for mortality prediction. It remains the <strong>gold standard</strong> for quantifying organ dysfunction in critically ill patients.',
    },
  },

  // === DISCLAIMER FOOTER ===
  disclaimer: {
    title: 'CLINICAL DISCLAIMER:',
    text: 'SOFA Score is a prognostic tool, does not replace clinical assessment. Interpret in complete clinical context of the patient.',
  },
};
